{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:44:18Z","timestamp":1787071458016,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Survodutide is a twincretin having dual glucagon-like peptide-1 and glucagon receptor agonist activity, conceptually based on endogenous peptide oxyntomodulin. This systematic review and meta-analysis (SRM) holistically analyzed the body weight lowering, glycemic efficacy, and safety of survodutide. Electronic databases were searched for RCTs involving diabetes and\/or obesity patients receiving once-weekly subcutaneous survodutide in intervention arm and placebo\/active comparator in control arm. Co-primary outcomes were the percent changes in body weight and HbA1c. Secondary outcomes were to evaluate absolute changes in absolute weight, blood pressure, fatty-liver disease parameters, and adverse events (AEs). Data from 3 RCTs (1088 patients) having follow-up duration ranging from 4\u201311 months were analyzed. Survodutide at 2.4 mg [MD (mean difference) \u22127.79% (95% confidence interval [CI]: \u221211.54, \u22124.07);\n                    <jats:italic toggle=\"yes\">I2 =<\/jats:italic>\n                    98%;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.01] and 3.6 mg [MD \u2212 9.08% (95% CI: \u221211.63, \u22126.54);\n                    <jats:italic toggle=\"yes\">I2 =<\/jats:italic>\n                    96%;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.001] was associated with significantly greater percent reductions in body weight compared to placebo. The corresponding absolute body-weight reduction with survodutide 2.4 mg and 3.6 mg was \u2212 9.14 kg (95% CI: \u221213.76, \u22124.53) and \u2212 10.23 kg (95% CI: \u221215.43, \u22125.04), respectively. Survodutide of 2.4 mg was associated with significant HbA1c reduction [MD: \u22120.88% (95% CI \u2212 1.72, \u22120.05);\n                    <jats:italic toggle=\"yes\">I2 =<\/jats:italic>\n                    99%;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.040]. Survodutide of 2.4 mg [odds ratio (OR): 2.93 (95% CI: 1.66, 5.18);\n                    <jats:italic toggle=\"yes\">I2 =<\/jats:italic>\n                    0%;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.001] and 3.6 mg [OR: 4.61 (95% CI: 2.33, 9.12);\n                    <jats:italic toggle=\"yes\">I2 =<\/jats:italic>\n                    0%;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.001] was associated with significantly higher treatment-emergent AEs, compared to placebo, although severe AEs were not increased. Gastrointestinal AEs were the predominant AEs and were dose dependent. Treatment discontinuation due to AEs was significantly higher with survodutide and was dose dependent. Survodutide demonstrates impressive weight and glucose-lowering properties over short-term clinical use. The optimal dose for clinical use ranges from 2.4 to 4.8 mg\/week.\n                  <\/jats:p>","DOI":"10.4103\/ijem.ijem_366_24","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T12:00:30Z","timestamp":1751112030000},"page":"253-259","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis"],"prefix":"10.4103","volume":"29","author":[{"given":"Deep","family":"Dutta","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Center for Endocrinology, Diabetes, Arthritis and Rheumatism (CEDAR) Superspeciality Healthcare, Dwarka, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abul B. M.","family":"Kamrul-Hasan","sequence":"additional","affiliation":[{"name":"Mymensingh Medical College, Mymensingh, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameya","family":"Joshi","sequence":"additional","affiliation":[{"name":"Bhaktivedanta Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Dhall","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Janakpuri Superspeciality Hospital, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Nagendra","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meha","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Center for Endocrinology, Diabetes, Arthritis and Rheumatism (CEDAR) Superspeciality Healthcare, Dwarka, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,28]]},"reference":[{"key":"R1-20250628","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/sj.ijo.0803344","article-title":"Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: A randomised controlled trial","volume":"30","author":"Wynne","year":"2006","journal-title":"Int J Obes"},{"key":"R2-20250628","doi-asserted-by":"crossref","first-page":"e2303696120","DOI":"10.1073\/pnas.2303696120","article-title":"Structural analysis of the dual agonism at GLP-1R and GCGR","volume":"120","author":"Li","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R3-20250628","doi-asserted-by":"crossref","first-page":"110779","DOI":"10.1016\/j.diabres.2023.110779","article-title":"Perspectives in weight control in diabetes \u2013Survodutide","volume":"207","author":"Klein","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"R4-20250628","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat Metab"},{"key":"R5-20250628","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A Phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"R6-20250628","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","article-title":"Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: A randomised clinical trial","volume":"67","author":"Bl\u00fcher","year":"2024","journal-title":"Diabetologia"},{"key":"R7-20250628","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: A randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R8-20250628","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jhep.2024.06.003","article-title":"Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon\/glucagon-like peptide-1 receptor dual agonist, in cirrhosis","volume":"81","author":"Lawitz","year":"2024","journal-title":"J Hepatol"},{"key":"R9-20250628","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R10-20250628","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R11-20250628","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R12-20250628","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3803\/EnM.2020.818","article-title":"Efficacy and safety of the novel dipeptidyl peptidase-4 inhibitor gemigliptin in the management of type 2 diabetes: A meta-analysis","volume":"36","author":"Dutta","year":"2021","journal-title":"Endocrinol Metab Seoul Korea"},{"key":"R13-20250628","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R14-20250628","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.dsx.2020.08.039","article-title":"Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis","volume":"14","author":"Dutta","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"R15-20250628","doi-asserted-by":"crossref","first-page":"107031","DOI":"10.1016\/j.phrs.2023.107031","article-title":"Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis","volume":"199","author":"Ding","year":"2024","journal-title":"Pharmacol Res"},{"key":"R17-20250628","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4103\/ijem.ijem_423_21","article-title":"Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis","volume":"25","author":"Dutta","year":"2021","journal-title":"Indian J Endocr Metab"},{"key":"R18-20250628","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00125-017-4354-8","article-title":"GLP-1\/glucagon receptor co-agonism for treatment of obesity","volume":"60","author":"S\u00e1nchez-Garrido","year":"2017","journal-title":"Diabetologia"},{"key":"R19-20250628","doi-asserted-by":"crossref","first-page":"120188","DOI":"10.1016\/j.lfs.2021.120188","article-title":"The current significance and prospects for the use of dual receptor agonism GLP-1\/Glucagon","volume":"288","author":"Spezani","year":"2022","journal-title":"Life Sci"},{"key":"R20-20250628","doi-asserted-by":"crossref","first-page":"1309118","DOI":"10.3389\/fendo.2024.1309118","article-title":"Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: A systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Nalisa","year":"2024","journal-title":"Front Endocrinol"},{"key":"R21-20250628","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12902-022-01031-5","article-title":"Impact of Cotadutide drug on patients with type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"22","author":"Ali","year":"2022","journal-title":"BMC Endocr Disord"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_366_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:46:26Z","timestamp":1787067986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_366_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_366_24","relation":{},"ISSN":["2230-8210","2230-9500"],"issn-type":[{"value":"2230-8210","type":"print"},{"value":"2230-9500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"2024-09-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}